GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (FRA:CUS0) » Definitions » EPS (Diluted)

Curis (FRA:CUS0) EPS (Diluted) : €-7.17 (TTM As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Curis EPS (Diluted)?

Curis's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was €-1.53. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-7.17.

Curis's EPS (Basic) for the three months ended in Sep. 2024 was €-1.53. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was €-7.17.

Curis's EPS without NRI for the three months ended in Sep. 2024 was €-1.53. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was €-7.17.

During the past 3 years, the average EPS without NRIGrowth Rate was 9.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Curis's highest 3-Year average EPS without NRI Growth Rate was 68.00% per year. The lowest was -34.50% per year. And the median was 13.35% per year.


Curis EPS (Diluted) Historical Data

The historical data trend for Curis's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curis EPS (Diluted) Chart

Curis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.46 -10.03 -8.85 -11.46 -8.22

Curis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.00 -1.86 -1.89 -1.89 -1.53

Competitive Comparison of Curis's EPS (Diluted)

For the Biotechnology subindustry, Curis's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's PE Ratio distribution charts can be found below:

* The bar in red indicates where Curis's PE Ratio falls into.



Curis EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Curis's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-43.478-0)/5.293
=-8.21

Curis's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as

Diluted EPS (Q: Sep. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-9.093-0)/5.941
=-1.53

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curis  (FRA:CUS0) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Curis EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Curis's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Curis Business Description

Traded in Other Exchanges
Address
128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis Headlines

No Headlines